Esposito Pamela 4

What Happened
Pamela Esposito, a director of Kymera Therapeutics (KYMR), exercised stock options and sold shares on March 20, 2026. She acquired 2,500 shares by exercising options at $49.10 per share (cost = $122,750). On the same day she sold a total of 2,500 shares in the open market for aggregate proceeds of approximately $197,877 (three sale lots). The filing also shows a disposition of 2,500 shares at $0.00 associated with an option exercise (see context below). The sales were executed under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: March 20, 2026. Transaction codes: M = option exercise, S = open-market sale.
• Option exercise (acquired): 2,500 shares @ $49.10 — total cost $122,750.
• Option-related disposition (reported at $0.00): 2,500 shares (likely net share settlement/withholding).
• Open-market sales (total 2,500 shares, proceeds ≈ $197,877):
  • 700 shares, weighted avg $77.71 (sales prices ranged $77.46–$77.98) — proceeds $54,398.
  • 600 shares, weighted avg $79.24 (range $78.70–$79.63) — proceeds $47,546.
  • 1,200 shares, weighted avg $79.94 (range $79.73–$80.27) — proceeds $95,933.
• Footnotes: Trades were effected under a Rule 10b5-1 plan (Sept 17, 2025). The option shares were fully vested and exercisable. The filing provides weighted-average sale prices and commits to disclose per-share breakdown upon request.
• Shares owned after the transactions: not specified in this Form 4.
• Filing timeliness: report filed March 20, 2026 (same-day reporting; not indicated as late).

Context

• Code M indicates option exercise. The $0.00 disposition commonly reflects shares withheld or surrendered to cover taxes or exercise obligations (a net settlement), not a market sale. Separately, the reported open-market sales were planned under a 10b5-1 program, which is a pre-arranged trading plan that can limit the informational value of the sales as a signal.
• For retail investors: exercises show the insider converted options into stock (and may retain or sell some shares); sales under a 10b5-1 plan are often routine. This filing records a mix of exercise and sales, with net cash received from market sales exceeding the cash paid to exercise the reported lot.